CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$2.46
-0.11 (-4.28%)
▼
5d:
-13.68%
30d:
-3.15%
90d:
+105.0%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
CDXS is down 13.7% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 92 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CDXS is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CDXS is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $2.46, which is considered slightly high relative to its 30-day fair value range of $2.22 to $2.76. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.7) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is currently testing key support at $2.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.58 (+167.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is currently testing key support at $2.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.58 (+167.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.22 -
$2.76
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 167.6% below Wall St target ($6.58)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -13.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.22 -
$2.76
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.40
Resistance Level
$2.98
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.65
Wall Street Target
$6.58
(+167.6%)
Revenue Growth (YoY)
102.1%
Profit Margin
-41.0%
PE vs Historical
-6.7 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: May 18, 2026 7:29 AM ET
Data refreshes hourly during market hours. Next update: 8:28 AM
Data refreshes hourly during market hours. Next update: 8:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Stefan Lutz
SELL
5862 shares
2026-02-24
Alison Moore
SELL
3826 shares
2026-02-06
Georgia Erbez
SELL
3826 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 60 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$181 | 61 BUY |
